FH and renal cell adenocarcinoma: The median relapse-free survival for patients with FH gene mutation was only 9 months, so the 2022 WHO classification of renal cell carcinoma has changed the term from HLRCC to FH-deficient RCC which represents a new subtype in nccRCC.